Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CMC Biologics To Manufacture IND Materials | Contract Pharma

What are you searching for?

Sign in
Breaking News

CMC Biologics To Manufacture IND Materials

Will provide material for toxicology and Phase I studies of OS2966

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CMC Biologics and OncoSynergy have entered an agreement for development and manufacture of material for early toxicology testing and cGMP material for IND toxicology studies and Phase I trials to advance OncoSynergy’s OS2966 monoclonal antibody program.
 
The program is based on OncoSynergy’s “Targeted Synergy” approach allowing broad inhibition of multiple fundamental cancer growth mechanisms with a single drug. OncoSynergy EU SAS in France will lead the project and CMC Biologics will provide cell-line development, process development, analytical development from its Copenhagen manufacturing facility. 
 
“We look forward to helping advance OncoSynergy’s OS2966 drug platform targeting cancers resistant to currently available therapies,” said Gustavo Mahler, global chief operations officer of CMC Biologics. “This contract highlights CMC Biologics’ proven and trusted platform for monoclonal antibody development and manufacturing.”
 
“We are impressed with CMC Biologics’ experience and technical competency in biopharmaceutical development and cGMP manufacturing,” said OncoSynergy co-founder and chief executive officer, Shawn Carbonell, M.D., Ph.D. “Choosing a partner who can provide a complete solution — from expression of the sequence of interest to providing material suitable for clinical trials — was a critical decision as we advance our lead candidate. They have also shown flexibility to accommodate our unique program needs as a virtual startup company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics